Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

769
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

950
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
950
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

496
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
496
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

470
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
470

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022-2023.

Frontiers in public health·2026
Same author

A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis.

Seminars in arthritis and rheumatism·2026
Same author

Pulmonary manifestations of granulomatosis with polyangiitis and microscopic polyangiitis.

Seminars in arthritis and rheumatism·2026
Same author

Heterogeneity in the association of genetic risk for RA and resultant RA phenotypes.

Rheumatology (Oxford, England)·2026
Same author

Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk.

Arthritis care & research·2025
Same author

Performance of an Idiopathic Pulmonary Fibrosis-Derived Multibiomarker Panel for Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Biomarkers in vasculitis.

Paul A Monach1

  • 1Boston University School of Medicine, Boston, MA, USA.

Current Opinion in Rheumatology
|November 22, 2013
PubMed
Summary
This summary is machine-generated.

New biomarkers show promise for managing vasculitis, with gene signatures and urinary proteins aiding diagnosis and relapse prediction. Further validation is needed to meet clinical utility standards for these novel diagnostic markers.

More Related Videos

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

17.0K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K

Related Experiment Videos

Last Updated: May 5, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

17.0K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K

Area of Science:

  • Immunology
  • Biomarker Discovery
  • Clinical Diagnostics

Background:

  • Vasculitis management requires improved biomarkers for patient guidance.
  • Advances in technology and large patient cohorts fuel preclinical biomarker research.

Purpose of the Study:

  • To review recent advancements in potential biomarkers for vasculitis.
  • To highlight novel diagnostic and prognostic markers identified through 'omics' and hypothesis-driven studies.

Main Methods:

  • Review of preclinical studies and recent findings on vasculitis biomarkers.
  • Analysis of gene expression signatures, urinary proteins, and circulating proteins.
  • 'Omics' technologies and conventional hypothesis-based approaches were utilized.

Main Results:

  • A CD8+ T cell gene signature predicts relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
  • Urinary proteins distinguish Kawasaki disease from other febrile illnesses.
  • Several circulating proteins (e.g., pentraxin-3, vWF antigen, eotaxin-3, MMP-3) show potential for specific vasculitis types.

Conclusions:

  • Emerging blood and urine biomarkers may aid vasculitis diagnosis, staging, activity assessment, and prognosis.
  • Demonstrating high sensitivity or specificity for clinically relevant outcomes remains a challenge for widespread clinical adoption.